Influence of methylenetetrahydrofolate reductase gene polymorphisms on the outcome of pediatric patients with non-Hodgkin lymphoma treated with high-dose methotrexate

Leukemia and Lymphoma

Volumn 54, Issue 12, 2013, Pages 2639-2644

  D'Angelo, Velia ^a   Ramaglia, Maria ^a   Iannotta, Adriana ^a   Francese, Matteo ^a   Pota, Elvira ^a   Affinita, Maria Carmen ^a   Pecoraro, Giulia ^a   Indolfi, Cristiana ^a   Di Martino, Martina ^a   Di Pinto, Daniela ^a   Buffardi, Salvatore ^b   Poggi, Vincenzo ^b   Indolfi, Paolo ^a   Casale, Fiorina ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b SANTOBONO PAUSILIPON CHILDREN S HOSPITAL   (Italy)

Author keywords

Methotrexate; MTHFR; Non Hodgkin lymphoma; SNPs

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); DNA FRAGMENT; METHOTREXATE;

ARTICLE; BLOOD TOXICITY; CANCER RECURRENCE; CANCER SURVIVAL; CHILDHOOD CANCER; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT; WILD TYPE;

ANTIMETABOLITES, ANTINEOPLASTIC; CHILD; ENZYME INHIBITORS; FEMALE; GENOTYPE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); NEOPLASM STAGING; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; TOXICOGENETICS; TREATMENT OUTCOME;

EID: 84887225641     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.784758     Document Type: Article

References (28)

1. De Mattia E, Toff oli G. C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fl uoropyrimidine based therapy. Eur J Cancer 2009;60:1-19.
2. Gemmati D, Ongaro A, Tognazzo S, et a l. Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin' s lymphoma patients: association with toxicity and survival. Haematologica 2007;92:478-485.
3. Kim HN, Kim YK, Lee IK, et a l. Association between polymorphisms of folate-metabolizing enzymes and haematological malignancies. Leuk Res 2009;33:82-87.
4. Bottiger AK, Hurtig-Wennlof A, Sjostrom M, et a l. Association of total plasma homocysteine with methylenetetrahydrofolate reductase genotypes 677C-T, 1298A-C, and 1793G-A and the corresponding haplotypes in Swedish children and adolescents. Int J Mol Med 2007;19:659-665.
5. Kremer JM. Methotrexate pharmacogenomics. Ann Rheum Dis 2006;65:1121-1123.
6. D' A ngelo V, Ramaglia M, Iannotta A, et a l. Methotrexate toxicity and effi cacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants. Cancer Chemother Pharmacol 2011;68:1339-1346.
7. Yang L, Hu X, Xu LH. Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-indued toxicity in acute lymphoblastic leukemia: a meta-analysis. Tumor Biol 2012;33:1445-1454.
8. Reiter A, Schrappe M, Parwaresch R, et a l. Non-Hodgkin' s lymphomas of childhood and adolescence: results of a treatment stratifi ed for biologic subtypes and stage-a report of the Berlin-Frankfurt-M ü nster group. J Clin Oncol 1995;13:359-372.
9. Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood 2005;105:948-958.
10. Harris NL, Jaff e ES, Diebold J, et al. World Health Organization classifi cation of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-3849.
11. WHO handbook for reporting results of cancer treatment. WHO off set publication no. 48. Geneva: World Health Organization; 1979.
12. Boyle E, Steinbuchn M, Tekautz T, et a l. Accuracy of DNA amplifi cation from archival haematological slides for use in genetic biomarker studies. Cancer Epidemiol 1998;7:1127-1131.
13. Weisberg I, Tran P, Christensen B, et al. A second genetic polymorphism in methylentetrahydofolaten reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998;64:169-172.
14. Murphy SB. Classifi cation, staging and end results of treatment in childhood non Hodgkin' s lymphoma: dissimilarities from lymphomas in adults. Semin Oncol 1980;7:332-339.
15. Krajinovic M, Moghrabi A. Pharmacogenetics of methotrexate. Pharmacogenomics 2004;5:819-834.
16. El-Khodary NM, EL-Haggar SM, Eid MA, et a l. Study of the pharmacokinetic and pharmacogenetic contribution to the toxicity of high-dose methotrexate in children with acute lymphoblastic leukemia. Med Oncol 2012;29:2053-2062.
17. Costea I, Moghrabi A, Laverdiere C, et al. Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia. Haematologica 2006;91:1113-1116.
18. Shimasaki N, Mori T, Samejima H, et al. Eff ects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol 2006;28:64-68.
19. Horinouchi M, Yagi M, Imanishi H, et al. Association of genetic polymorphismis with hepatotoxicity in patients with chilhood acute lymphoblastic leukemia or lymphoma. Pediatr Hematol Oncol 2010;27:344-354.
20. Erc ulj N, Kotnik BF, Debeljak M, et al. Infl uence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia. Leuk Lymphoma 2012;53:1096-1104
21. Ongaro A, De Mattei M, Della Porta MG, et al. Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: eff ects on methotrexate-related toxicity and survival. Haematologica 2009;94:1391-1398.
22. Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol 2009;146:489-503.
23. Gervasini G. Polymorphisms in methotrexate pathways: what is clinically relevant, what is not, and what is promising. Curr Drug Metab 2009;10:547-566.
24. Kim YI. Role of the MTHFR polymorphisms in cancer risk modifi cation and treatment. Future Oncol 2009;5:523-542.
25. Kantar M, Kosova B, Centingul N, et a l. Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma 2009; 50:912-917.
26. Seidemann K, Book M, Zimmermann M, et a l. MTHFR 677 (C T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95. Ann Hematol 2006;85:291-300.
27. Cunningham L, Aplenc R. Role of the folate-pathway and the thymidylate synthase genes in pediatric acute lymphoblastic leukemia treatment response. In: Innocenti F, editor. Genomics and pharmacogenomics in anticancer drug development and clinical response. Totowa, NJ: Humana Press 2008. pp 299-312.
28. Chiusolo P, Giammarco S, Bellesi S, et a l. The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with haematological malignancies treated with high-dose methotrexate followed by leucovorin rescue. Cancer Chemother Pharmacol 2012; 69:691-696.